Infectious diseases and increasing antibiotic resistance among diverse classes of microbes are global health concerns and a prime focus of omics systems science applications in novel drug discovery. Plumbagin is a plant-derived naphthoquinone, a natural product that exhibits antibacterial activity against gram-positive bacteria. In the present study, we investigated the antimicrobial effects of plumbagin against Bacillus subtilis using two complementary proteomics techniques: two-dimensional electrophoresis (2-DE) and isobaric tag for relative and absolute quantification (iTRAQ). Comparative quantitative proteomics analysis of plumbagin treated and untreated control samples identified differential expression of 230 proteins (1% FDR, 1.5 fold-change and ≥2 peptides) in B. subtilis after plumbagin treatment. Pathway analysis involving the differentially expressed proteins suggested that plumbagin effectively increases heme and protein biosynthesis, whereas fatty acid synthesis was significantly reduced. Gene expression and metabolic activity assays further corroborated the proteomics findings. We anticipate that plumbagin blocks the cell division by altering the membrane permeability required for energy generation. This is the first report, to the best of our knowledge, offering new insights, at proteome level, for the putative mode(s) of action of plumbagin and attendant cellular targets in B. subtilis. The findings also suggest new ways forward for the modern omics-guided drug target discovery, building on traditional plant medicine.
Get full access to this article
View all access options for this article.
References
1.
AcharyaBR, BhattacharyyaB, and ChakrabartiG. (2008). The natural naphthoquinone plumbagin exhibits antiproliferative activity and disrupts the microtubule network through tubulin binding. Biochemistry, 47, 7838–7845.
2.
BhattacharyaA, JindalB, SinghP, DattaA, and PandaD. (2013). Plumbagin inhibits cytokinesis in Bacillus subtilis by inhibiting FtsZ assembly: A mechanistic study of its antibacterial activity. FEBS J, 280, 4585–4599.
3.
CambergJL, HoskinsJR, and WicknerS. (2011). The interplay of ClpXP with the cell division machinery in Escherichia coli. J Bacteriol, 193, 1911–1918.
4.
ChenJW, SunCM, ShengWL, WangYC, and SyuWJ. (2006). Expression analysis of up-regulated genes responding to plumbagin in Escherichia coli. J Bacteriol, 188, 456–463.
ChristianKA, IjazK, DowellSF, et al. (2013). What we are watching—five top global infectious disease threats, 2012: A perspective from CDC's Global Disease Detection Operations Center. Emerg Health Threats J, 6, 20632.
7.
CortialS, ChaignonP, IorgaBI, et al. (2010). NADH oxidase activity of Bacillus subtilis nitroreductase NfrA1: Insight into its biological role. FEBS Lett, 584, 3916–3922.
8.
Cruz RamosH, HoffmannT, MarinoM, et al. (2000). Fermentative metabolism of Bacillus subtilis: Physiology and regulation of gene expression. J Bacteriol, 182, 3072–3080.
9.
CurreliN, SollaiF, MassaL, et al. (2001). Effects of plant-derived naphthoquinones on the growth of Pleurotus sajor-caju and degradation of the compounds by fungal cultures. J Basic Microbiol, 41, 253–259.
10.
de PaivaSR, FigueiredoMR, AragãoTV, and KaplanMA. (2003). Antimicrobial activity in vitro of plumbagin isolated from Plumbago species. Mem Inst Oswaldo Cruz, 98, 959–691.
11.
EdenharderR, and TangX. (1997). Inhibition of the mutagenicity of 2-nitrofluorene, 3-nitrofluoranthene and 1-nitropyrene by flavonoids, coumarins, quinones and other phenolic compounds. Food Chem Toxicol, 35, 357–372.
12.
FeuchtA, LucetI, YudkinMD, and ErringtonJ. (2001). Cytological and biochemical characterization of the FtsA cell division protein of Bacillus subtilis. Mol Microbiol, 40, 115–125.
13.
FossMH, EunYJ, GroveCI, et al. (2013). Inhibitors of bacterial tubulin target bacterial membranes in vivo. Med Chem Comm, 4, 112–119.
14.
GomathinayagamR, SowmyalakshmiS, MardhatillahF, KumarR, AkbarshaMA, and DamodaranC. (2008). Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells. Anticancer Res, 28, 785–792.
15.
HaeusserDP, LeeAH, WeartRB, and LevinPA. (2009). ClpX inhibits FtsZ assembly in a manner that does not require its ATP hydrolysis-dependent chaperone activity. J Bacteriol, 191, 1986–1991.
16.
HandlerAA, LimJE, and LosickR. (2008). Peptide inhibitor of cytokinesis during sporulation in Bacillus subtilis. Mol Microbiol, 68, 588–599.
17.
HaySI, BattleKE, PigottDM, et al. (2013). Global mapping of infectious disease. Philos Trans R Soc Lond B Biol Sci, 368, 20120250.
18.
HaySI, GeorgeDB, MoyesCL, and BrownsteinJS. (2013). Big data opportunities for global infectious disease surveillance. PLoS Med, 10, e1001413.
19.
HuangDW, ShermanBT, and LempickiRA. (2009a). Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res, 37, 1–13.
20.
HuangDW, ShermanBT, and LempickiRA. (2009b). Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nature Protoc, 4, 44–57.
21.
HueyR, MorrisGM, OlsonAJ, and GoodsellDS. (2007). A semiempirical free energy force field with charge-based desolvation. J Comput Chem, 28, 1145–1152.
22.
ImlayJ, and FridovichI. (1992). Exogenous quinones directly inhibit the respiratory NADH dehydrogenase in Escherichia coli. Arch Biochem Biophys, 296, 337–346.
23.
JaiswalR, BeuriaTK, MohanR, MahajanSK, and PandaD. (2007). Totarol inhibits bacterial cytokinesis by perturbing the assembly dynamics of FtsZ. Biochemistry, 46, 4211–4220.
24.
KaraosmanogluK, SayarNA, KurnazIA, and AkbulutBS. (2014). Assessment of berberine as a multi-target antimicrobial: A multi-omics study for drug discovery and repositioning. OMICS, 18, 42–53.
25.
KockH, GerthU, and HeckerM. (2004). MurAA, catalysing the first committed step in peptidoglycan biosynthesis, is a target of Clp-dependent proteolysis in Bacillus subtilis. Mol Microbiol, 51, 1087–1102.
26.
KohlerC, von EiffC, PetersG, ProctorRA, HeckerM, and EngelmannS. (2003). Physiological characterization of a heme-deficient mutant of Staphylococcus aureus by a proteomic approach. J Bacteriol, 185, 6928–6937.
27.
KrügerE, WittE, OhlmeierS, HanschkeR, and HeckerM. (2000). The clp proteases of Bacillus subtilis are directly involved in degradation of misfolded proteins. J Bacteriol, 182, 3259–3265.
28.
KrungkraiJ, KanchanarithisakR, KrungkraiSR, and RochanakijS. (2002). Mitochondrial NADH dehydrogenase from Plasmodium falciparum and Plasmodium berghei. Exp Parasitol, 100, 54-961.
29.
LinCN, SyuWJ, SunWS, et al. (2010). A role of ygfZ in the Escherichia coli response to plumbagin challenge. J Biomed Sci, 17, 84.
30.
LuoP, WongYF, GeL, et al. (2010). Anti-inflammatory and analgesic effect of plumbagin through inhibition of nuclear factor-κB activation. J Pharmacol Exp Ther, 335, 735–742.
31.
MarinoM, HoffmannT, SchmidR, MöbitzH, and JahnD. (2000). Changes in protein synthesis during the adaptation of Bacillus subtilis to anaerobic growth conditions. Microbiology, 146, 97–105.
32.
MatsunoK, and SonensheinAL. (1999). Role of SpoVG in asymmetric septation in Bacillus subtilis. J Bacteriol, 181, 3392–3401.
33.
MöbiusK, Arias-CartinR, BreckauD, et al. (2010). Heme biosynthesis is coupled to electron transport chains for energy generation. Proc Natl Acad Sci USA, 107, 10436–41041.
34.
NeuhausJM, and WrightJK. (1983). Chemical modification of the lactose carrier of Escherichia coli by plumbagin, phenylarsinoxide or diethylpyrocarbonate affects the binding of galactoside. Eur J, 137, 615–621.
35.
PaolettiL, LuYJ, SchujmanGE, de MendozaD, and RockCO. (2007). Coupling of fatty acid and phospholipid synthesis in Bacillus subtilis. J Bacteriol, 189, 5816–5824.
36.
PlichtaJK, NienhouseV, and RadekKA. (2012). Integrating “omics” technologies to conceptualize dynamic antimicrobial peptide responses. Front Immunol 2012, 3, 284.
37.
PoglianoJ, PoglianoN, and SilvermanJA. (2012). Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. J Bacteriol, 194, 4494–4504.
38.
RaiD, SinghJK, RoyN, and PandaD. (2008). Curcumin inhibits FtsZ assembly: An attractive mechanism for its antibacterial activity. Biochem J, 410, 147–155.
39.
RaoAA, PatkariM, ReddyPJ, et al. (2014). Proteomic analysis of Streptomyces coelicolor in response to ciprofloxacin challenge. J Proteomics, 97, 222–234.
40.
ReddyPJ, RaoAA, MalhotraD, et al. (2013). A simple protein extraction method for proteomic analysis of diverse samples. Curr Proteomics, 10, 298–311.
41.
RoyA, KucukuralA, and ZhangY. (2010). I-TASSER: A unified platform for automated protein structure and function prediction. Nature Protoc, 5, 725–738.
42.
ShevchenkoA, TomasH, HavlisJ, OlsenJV, and MannM. (2006). In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc, 1, 2856–2860.
43.
StrahlH, and HamoenLW. (2010). Membrane potential is important for bacterial cell division. Proc Natl Acad Sci USA, 107, 12281–12286.
44.
SunN, ChanFY, LuYJ, et al. (2014). Rational design of berberine-based FtsZ inhibitors with broad-spectrum antibacterial activity. PLoS One, 9, e97514.
45.
WeckeT, and MascherT. (2011). Antibiotic research in the age of omics: From expression profiles to interspecies communication. J Antimicrob Chemother, 66, 2689–2704.
46.
WenzelM, KohlB, MünchD, et al. (2012). Proteomic response of Bacillus subtilis to lantibiotics reflects differences in interaction with the cytoplasmic membrane. Antimicrob Agents Chemother, 56, 5749–5757.
47.
XieC, MaoX, HuangJ, et al. (2011). KOBAS 2.0: A web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res, 39,(Web Server issue),W316–322.
48.
YeRW, TaoW, BedzykL, YoungT, ChenM, and LiL. (2000). Global gene expression profiles of Bacillus subtilis grown under anaerobic conditions. J Bacteriol, 182, 4458–4465.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
